A New Resource for MPN patients

MPN Cancer Connection


Welcome to MPN Cancer Connection, where a brighter future for MPN patients shines on the horizon with opportunity, new treatments and resources for improved patient care.


Are Myeloproliferative Neoplasms (MPNs) Cancer?

This is one of the most frequently asked questions by newly diagnosed patients, and one not clearly understood by many hematologist at the local level. YES indeed, MPNs including Polycythemia Vera, Myelofibrosis and Essential Thrombocythemia are blood cancers. That is why the term was changed from myeloproliferative disorder to myeloproliferative neoplasm.

What Are Myeloproliferative Neoplasms?

Myeloproliferative neoplasms (MPN) are a group of diseases that affect blood-cell formation. In all forms of MPN, a bone marrow problem leads to increased levels of blood cells circulating in the bloodstream. .
1) “Myelo” refers to bone marrow, which is the body’s blood-cell factory.
2) “Proliferative” refers to the rapid growth and production of cells.
3) “Myeloproliferative” means increased growth and production of bone marrow and blood cells.
4) “Neoplasm” means an abnormal growth of cells, especially as a characteristic of cancer.

Clinical Trial Finder

Clinical Trial Finder

Free, No Personal Information Required

Search for MPN Clinical Trials that may help you find new treatments and medical approaches for your myelofibrosis (MF), polycythemia vera (PV) or essential thrombocythemia (ET).

ClinicalTrials.gov is difficult to use for patients, as it is primarily a resource for doctors and clinicians.  Our Clinical Trial Finder restructures the trial information - providing "easy access" while improving patient's understanding of the trial.


Learn More

Learn more about MPN (Myeloproliferative Neoplasms)
David Wallace, our CEO, is recognized as a 2016 MPN Hero for his commitment to helping newly diagnosed patients with myeloproliferative neoplasms (MPNs) learn about their condition. He founded MPN Cancer Connection with the vision of sharing his experience as an "outspoken patient advocate" to help fellow patients get up to speed quickly and have the tools necessary to make educated decisions on treatment options.
Dr. Ruben Mesa - MPN Update Summer 2021 Ruben Mesa, M.D., executive director, at UT Health San Antonio MD Anderson Cancer Center, provides an update on disease burden, current treatments, and new therapies in developments (including clinical trials) on the myeloproliferative neoplasms (MPNs) including Systemic Mast Cell Disease (SM), essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF).


December 30, 2021
prescription for Ropeg

New FDA Approved Treatment for Polycythemia Vera

by David Wallace Patients are Asking – MPN Expert Dr. Abu-Zeinah discusses Ropeginterferon, FDA Approved Treatment for Polycythemia Vera Episode 3 of 3 Ropeginterferon / BESREMi […]
December 21, 2021
MPN community

The Health Benefits of Social Connections for Myeloproliferative Neoplasm Patients

by Lou Ann Donovan We all enjoy getting together with friends and attending family gatherings from time to time. Such occasions give us an opportunity to […]
November 30, 2021
stress in MPNs

Reducing MPN Related Stress with Mindfulness and Healthy Lifestyle

by Lou Ann Donovan Stress and the Body Stress is a natural physical and mental response to life experiences.  Some stress is even good and can […]

MPN Cancer Connection Mission

To continue helping MPN patients by expanding the wide range of resources & patient education programs. While empowering patients to better understand treatment options and improve patient care by recognizing MPNs are a cancer, offering access to a broad range of benefits and program assistance.

MPN Cancer Connection
Malcare WordPress Security